IL7R and neoplasm: Interestingly, IL7R− γδ TRM upregulates inhibitory molecules CTLA4 and PDCD1 in the TME more than IL7R+ γδ TRM, indicating that IL7R+ TRM may sustain longer life and provide a longer-lasting anti-tumor effect.